

1321

011304

# FITCH, EVEN, TABIN & FLANNERY

ATTORNEYS AND COUNSELLORS AT LAW

Established in 1859

MORGAN L. FITCH, JR.  
 FRANCIS A. EVEN\*  
 JAMES J. TABIN  
 JOHN F. FLANNERY  
 ROBERT B. JONES  
 JAMES J. SCHUMANN  
 JAMES J. HAMILL  
 TIMOTHY E. LEVSTIK  
 JOSEPH E. SHIPLEY  
 KENNETH H. SAMPLES  
 PHILIP T. PETTI  
 JOSEPH T. NABOR  
 STEVEN C. SCHROER  
 RICHARD A. KABA\*  
 KARL R. FINK  
 MARK W. HETZLER  
 TIMOTHY P. MALONEY  
 JAMES P. KRUEGER  
 STEPHEN S. FAVAKEH  
 EDWARD W. GRAY, JR.\*  
 RICHARD E. WAWRZYNIAK  
 STEVEN G. PARMELEE  
 SHERRI N. BLOUNT\*  
 BRUCE R. MANSFIELD  
 KENDREW H. COLTON\*  
 G. PAUL EDGELL\*  
 RICHARD W. SCHUMACHER  
 MICHAEL A. SANZO\*

SUITE 401L - 1801 K STREET, NW  
 WASHINGTON, D.C. 20006-1201  
 TELEPHONE (202) 419-7000  
 FACSIMILE (202) 419-7007

ILLINOIS OFFICE  
 SUITE 1600 - 120 SOUTH LA SALLE STREET, CHICAGO, ILLINOIS 60603-3406  
 TELEPHONE (312) 577-7000

CALIFORNIA OFFICE  
 SUITE 250 - 9276 SCRANTON ROAD, SAN DIEGO, CA 92121-7707  
 TELEPHONE (858) 552-1311

COLORADO OFFICE  
 SUITE 213 - 1942 BROADWAY, BOULDER, COLORADO 80302  
 TELEPHONE (303) 402-6966

CHRISTOPHER E. GEORGE\*  
 SCOTT J. MENGHINI  
 EDWARD E. CLAIR  
 SANDRA V. SCAVO  
 JON A. BIRMINGHAM  
 RUDY KRATZ  
 RAMON R. HOCH\*  
 JOHN E. LYHUS  
 STEVEN M. FREELAND  
 DONNA E. BECKER  
 SEAN R. O'DOWD  
 MICHAEL G. VRANICAR  
 BRIAN S. CLISE  
 MARTIN R. BADER  
 DEREK L. PRESTIN  
 MARK A. BORSOS  
 DAVID R. JAGLOWSKI  
 W. BRIAN EDGE\*

## PATENT AGENTS

ERIC J. WHITESELL  
 JONATHAN H. BACKENSTOSE  
 LILIA I. SAFONOV

## OF COUNSEL

THOMAS F. LEBENS  
 GEORGE W. SPELLMIRE, JR.  
 LISA M. SOMMER

January 13, 2004

\*ADMITTED TO D.C. BAR; D.C. PRACTICE OF  
 ALL OTHERS LIMITED TO FEDERAL COURTS  
 AND AGENCIES

Commissioner of Patents  
 U.S. Patent and Trademark Office  
 2011 South Clark Place  
 Customer Window, MS Patent Application  
 Crystal Plaza Two, Lobby, Room 1B03  
 Arlington, VA 22202

Re: New U.S. Patent Application  
 (Claiming Priority to Provisional Appl. No. 60/440,029)  
 Appl. No.: to be assigned  
 Filed: herewith  
 Title: **Eosinophil-Derived Neurotoxin as a  
 Marker for Ovarian Cancer**  
 Inventor(s): Ye, *et al.*  
 Atty. Dkt.: 7570/80962

Dear Sir:

The following documents are being forwarded for appropriate action by the U.S. Patent and Trademark Office:

1. U.S. Patent Application entitled:

**EOSINOPHIL-DERIVED NEUROTOXIN AS A  
 MARKER FOR OVARIAN CANCER**

and naming as inventor(s): Bin Ye  
 Daniel W. Cramer  
 Samuel C. Mok

17497 U.S.PTO  
 10/755854

011304

Commissioner of Patents  
January 13, 2004  
Page 2

the application comprising:

19 pages of Specification (numbered as pages 1-19),  
3 pages of Claims (numbered as pages 20-22),  
a one-page Abstract (numbered as page 23),  
3 sheets of Formal Drawings (labeled as Fig. 1 - Fig. 6), and  
2 pages of Sequence Listing (numbered separately as pages 1-2);

2. Declaration (37 C.F.R. § 1.63) and Power of Attorney of inventors Bin Ye, Daniel W. Cramer and Samuel C. Mok, unexecuted (4 pages);
3. Assignment to The Brigham and Women's Hospital, Inc. by inventors Bin Ye, Daniel W. Cramer and Samuel C. Mok, unexecuted (2 pages);
4. A 3.5 inch computer diskette containing a computer readable form of the Sequence Listing;
5. General Authorization for Petition for Extension of Time Under 37 C.F.R. § 1.136(a)(3);
6. General Authorization to Charge Deposit Account; and
7. Two (2) return postcards.

This application claims the benefit of U.S. provisional application no. 60/440,029, filed January 15, 2003, which is incorporated in its entirety herein by reference.

In accordance with 37 C.F.R. § 1.821(f), Applicants' undersigned attorney hereby states that the information recorded in the enclosed computer readable copy of the Sequence Listing and the paper copy of the Sequence Listing are the same.

A separate written request under 37 C.F.R. §1.136(a)(3), which is a general authorization to treat any concurrent or future reply requiring a petition for an extension of time under 37 C.F.R. §1.136(a) for its timely submission as incorporating a petition for an extension of time for the appropriate length of time, is enclosed.



13281  
011304  
U.S. PTO

Commissioner of Patents  
January 13, 2004  
Page 3

### Fee Calculation

Applicants calculate the filing fee is as follows (**Small Entity Status is claimed**):

	Total		No. Extra	Rate	Fee
<b>Basic Filing Fee</b>					<b>385.00</b>
<b>Total Claims Fee</b>	<b>42</b>	<b>20=</b>	<b>22</b>	<b>\$ 9.00</b>	<b>198.00</b>
<b>Independent Claims Fee</b>	<b>3</b>	<b>3 =</b>	<b>0</b>	<b>\$ 43.00</b>	<b>0.00</b>
<b>Multiple Dependent Claims Fee</b>				<b>\$ 145.00</b>	<b>145.00</b>
<b>TOTAL FEES DUE</b>					<b>\$ 728.00</b>

**The application is being filed under 37 C.F.R. § 1.53 without the declaration and without the filing fee.**

It is respectfully requested that the enclosed postcards be stamped with the date the enclosed documents are received by the PTO and the serial number and that they be returned as soon as possible.

Very truly yours,

FITCH, EVEN, TABIN & FLANNERY

Michael A. Sanzo  
Reg. No. 36,912  
Attorney for Applicants

MAS:ct  
Enclosures



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application of:

Ye, et al.

Art Unit: to be assigned

Appl. No.: to be assigned

Examiner: to be assigned

Filed: herewith

Atty. Dkt.: 7570/80962

For: **Eosinophil-Derived Neurotoxin as a  
Marker for Ovarian Cancer**

**General Authorization for Petition for  
Extension of Time Under 37 C.F.R. § 1.136(a)(3)**

Commissioner of Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
**Customer Window, MS Patent Application**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Sir:

Applicants hereby request under 37 C.F.R. §1.136(a)(3) by this general authorization that any concurrent or future reply submitted by Applicants to the United States Patent and Trademark Office for the above-identified patent application requiring a petition for an extension of time under §1.136(a) for its timely submission be treated as incorporating therein a petition for an extension of time for the appropriate length of time.

If Applicants do not timely pay for any extension fee(s) pursuant to 37 C.F.R. §1.136(a) which may become due for this application under 37 C.F.R. §1.17 by check, the Director is hereby authorized to charge such fee(s), and any additional fees which may be required in this application under 37 C.F.R. §§1.16-1.17 during its entire pendency, or credit any overpayment, to Deposit Account No. 06-1135 under Order No. 7570/80962.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By Michael A. Sanzo  
Michael A. Sanzo  
Reg. No. 36,912  
Attorney for Applicants

Date January 13, 2003  
1801 K Street, N.W., Suite 401L  
Washington, DC 20006-1201  
Phone: (202) 419-7013



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application of:

Ye, et al.

Art Unit: to be assigned

Appl. No.: to be assigned

Examiner: to be assigned

Filed: herewith

Atty. Dkt.: 7570/80962

For: **Eosinophil-Derived Neurotoxin as a  
Marker for Ovarian Cancer**

**General Authorization to Charge Deposit Account**

Commissioner of Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, **MS Patent Application**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Sir:

The Commissioner is hereby authorized to charge any additional fees which may be required in this application under 37 C.F.R. §§1.16-1.17 during its entire pendency, or credit any overpayment, to Deposit Account No. 06-1135 under Order No. 7570/80962.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By Michael A. Sanzo  
Michael A. Sanzo  
Reg. No. 36,912  
Attorney for Applicants

Date January 13, 2003  
1801 K Street, N.W. Suite 401L  
Washington, DC 20006-1201  
Phone: (202) 419-7013